IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

SCHUURMAN ET AL.

APPLICATION NO:

FILED:

FOR: COMBINATIONS OF IMMUNOSUPRESSIVE AGENTS FOR THE TREATMENT OR PREVENTION OF GRAFT REJECTIONS

Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above-referenced patent application, please amend the application as follows:

In the Claims:

Please cancel claim 4.

Please amend claims 5-6 as follows:

5. (Amended) A pharmaceutical composition according to claim 1 wherein the pharmaceutically acceptable salt of mycophenolic acid is MPA sodium salt formulated as an enteric-coated solid oral dosage form.

6. (Amended) A method for the treatment or prevention of xenograft rejection comprising administering a pharmaceutical composition according to claim 1.

Please add claims 10 and 11 as follows:

10. A pharmaceutical composition according to claim 2 wherein the pharmaceutically acceptable salt of mycophenolic acid is MPA sodium salt formulated as an enteric-coated solid oral dosage form.

11. A method for the treatment or prevention of xenograft rejection comprising administering a pharmaceutical composition according to claim 2.

REMARKS

Claims 5-6 have been amended, claims 10-11 have been added and claim 4 has been canceled. Favorable consideration of this application is respectfully requested.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "VERSIONS WITH MARKINGS TO SHOW CHANGES MADE."

Respectfully submitted,

Thomas R. Savitsky
Attorney for Applicants
Reg. No. 31,661

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6765

Date: November 7, 2001

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 5-6 have been amended as follows:

5. A pharmaceutical composition according to claim 1 ~~or 2~~ wherein the pharmaceutically acceptable salt of mycophenolic acid is MPA sodium salt formulated as an enteric-coated solid oral dosage form.

6. A method for the treatment or prevention of xenograft rejection comprising administering a pharmaceutical composition according to claim 1 ~~or 2~~.